Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

(2016) Richard F. Schlenk et al.   ANNALS OF HEMATOLOGY

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

(2016) N. Duployez et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

The genomic landscape of core-binding factor acute myeloid leukemias

(2016) Zachary J Faber et al.   NATURE GENETICS

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

(2015) N. Boissel et al.   HAEMATOLOGICA

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

(2015) N. Boissel et al.   HAEMATOLOGICA

High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia

(2015) Xiaoning Gao et al.   PLoS One

Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells

(2014) Nan Xie et al.   BIOCHEMICAL PHARMACOLOGY

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients

(2014) M. Tassara et al.   BLOOD

The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents

(2013) C. Dos Santos et al.   BLOOD

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

(2013) C Allen et al.   LEUKEMIA

MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia

(2013) Yanfen Fang et al.   PLoS One

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)

(2012) P. Paschka et al.   BLOOD

Cytarabine Dose for Acute Myeloid Leukemia

(2011) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

(2011) Y.-Y. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

KITmutations confer a distinct gene expression signature in core binding factor leukaemia

(2010) Sonja C. Lück et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A

(2010) Richard F. Schlenk et al.   JOURNAL OF CLINICAL ONCOLOGY

Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib

(2010) N Chevalier et al.   LEUKEMIA

Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors

(2010) P Pittoni et al.   ONCOGENE

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE